Therapeutic | Dupilumab |
Target | IL4R |
Heavy Chain | EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS |
Light Chain | DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK |
100% seqID Fv Structure | 6wg8 [Fvs: AB], 6wgb [Fvs: AB, CD], 6wgj [Fvs: AB, CD, EF], 6wgk [Fvs: AB, CD, EF, GH], 6wgl [Fvs: AB] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6wgb [Fvs: AB, CD] |
100% seqID Structure | 6wgj [Fvs: AB, CD, EF] |
100% seqID Structure | 6wgk [Fvs: AB, CD, EF, GH] |
100% seqID Structure | 6wgl [Fvs: AB] |
100% seqID Structure | 6wg8 [Fvs: AB] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | VelocImmune Mouse |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Aimmune Therapeutics, Regeneron Pharmaceuticals, Sanofi |
Conditions Approved | Asthma, Atopic dermatitis |
Conditions Active | Nasal polyps, Chronic obstructive pulmonary disease, Eosinophilic oesophagitis, Grass pollen hypersensitivity, Peanut hypersensitivity, Urticaria, Allergic asthma |
Conditions Discontinued | na |
Notes |